NO993121L - Stabile flytende interferon-formuleringer - Google Patents

Stabile flytende interferon-formuleringer

Info

Publication number
NO993121L
NO993121L NO993121A NO993121A NO993121L NO 993121 L NO993121 L NO 993121L NO 993121 A NO993121 A NO 993121A NO 993121 A NO993121 A NO 993121A NO 993121 L NO993121 L NO 993121L
Authority
NO
Norway
Prior art keywords
liquid
interferon
beta
stable liquid
liquid interferon
Prior art date
Application number
NO993121A
Other languages
English (en)
Other versions
NO327844B1 (no
NO993121D0 (no
Inventor
Mary D Dibiasi
Mark Staples
Wen-Li Chung
Eric Scharin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO993121(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO993121D0 publication Critical patent/NO993121D0/no
Publication of NO993121L publication Critical patent/NO993121L/no
Publication of NO327844B1 publication Critical patent/NO327844B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Flytende interferonsammensetningene som har en pH mellom 4,0 og 7,2 er beskrevet. Sammensetningene omfatter interferon-beta og et stabiliseringsmiddel ved mellom omkring 0,3 vekt% og 5 vekt% som er en aminosyre valgt fra gruppen omfattende sure aminosyrer, arginin og glysin. Om nødvendig blir salt tilsatt for å gi tilstrekkelig jodstyrke. Den flytende sammensetning har ikke på forhånd blitt fryse-tørket eller på forhånd blitt kavitert. Væsken er for-trinnsvis inneholdt i en beholder som har minst en over-flate i kontakt med væsken som er belagt med materiale som er inert overfor adsorpsjon av interferon-beta. Et sett for parenteral administrasjon av en flytende interferon-formulering samt en fremgangsmåte for å stabilisere flytende interferonsammensetningen er også beskrevet.
NO993121A 1996-12-24 1999-06-23 Pakket sett for administrasjon av interferon beta, flytende sammensetning for slikt sett samt fremgangsmåte for fremstilling derav NO327844B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (3)

Publication Number Publication Date
NO993121D0 NO993121D0 (no) 1999-06-23
NO993121L true NO993121L (no) 1999-08-24
NO327844B1 NO327844B1 (no) 2009-10-05

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993121A NO327844B1 (no) 1996-12-24 1999-06-23 Pakket sett for administrasjon av interferon beta, flytende sammensetning for slikt sett samt fremgangsmåte for fremstilling derav

Country Status (27)

Country Link
EP (1) EP0948358B2 (no)
JP (5) JP4878664B2 (no)
KR (2) KR20000069664A (no)
CN (2) CN1733296B (no)
AT (1) ATE270899T1 (no)
AU (1) AU738362B2 (no)
BG (2) BG65171B1 (no)
BR (1) BR9714434A (no)
CA (1) CA2275890C (no)
CZ (1) CZ300636B6 (no)
DE (1) DE69729880T3 (no)
DK (1) DK0948358T4 (no)
EA (1) EA002754B1 (no)
EE (2) EE04266B1 (no)
ES (1) ES2224290T5 (no)
HU (1) HU224222B1 (no)
IL (1) IL130524A (no)
IS (1) IS2070B (no)
MX (1) MX337876B (no)
NO (1) NO327844B1 (no)
NZ (2) NZ336548A (no)
PL (1) PL193447B1 (no)
PT (1) PT948358E (no)
SI (1) SI0948358T2 (no)
SK (1) SK284989B6 (no)
TR (1) TR199901968T2 (no)
WO (1) WO1998028007A1 (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
KR100767473B1 (ko) * 1999-05-31 2007-10-17 미쯔비시 가가꾸 가부시끼가이샤 간실질세포 증식인자 동결건조 제제
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
BRPI0416042A (pt) * 2003-11-13 2007-01-02 Alza Corp composição e aparelho para suprimento transdérmico
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
RU2373953C2 (ru) 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
EP1750750B1 (en) * 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PT1809662E (pt) * 2004-11-10 2009-02-26 Novartis Vaccines & Diagnostic Interferão beta desamidado
PT1845925T (pt) 2005-01-12 2016-11-22 Biogen Ma Inc Método para distribuir interferão-beta
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP1899462B1 (en) 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009133408A2 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2649993B1 (en) 2010-12-09 2017-04-05 Maruishi Pharmaceutical Co., Ltd. Stabilizer of acetaminophen
AU2012229104B2 (en) 2011-03-15 2017-03-16 Biogen Ma Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP2015515480A (ja) * 2012-04-19 2015-05-28 シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ エチレンオキシド滅菌下のｐＨ安定性が改善された注入液
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
ES2825704T3 (es) 2014-12-03 2021-05-17 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
MX2022013662A (es) * 2020-04-29 2023-02-01 Abion Inc Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
WO2022207655A1 (en) * 2021-03-30 2022-10-06 Schott Schweiz Ag System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
AU2022426492A1 (en) * 2021-12-27 2024-07-18 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (no) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物

Also Published As

Publication number Publication date
HUP0000829A2 (en) 2000-07-28
CN1733296A (zh) 2006-02-15
JP2001519770A (ja) 2001-10-23
EP0948358A1 (en) 1999-10-13
SK85899A3 (en) 2000-01-18
NZ336548A (en) 2001-09-28
EE04223B1 (et) 2004-02-16
EA199900597A1 (ru) 2000-02-28
SI0948358T1 (en) 2005-04-30
JP2011068694A (ja) 2011-04-07
BG103594A (en) 2000-04-28
JP4878664B2 (ja) 2012-02-15
BG65171B1 (bg) 2007-05-31
HK1092048A1 (zh) 2007-02-02
DE69729880D1 (de) 2004-08-19
IS5087A (is) 1999-06-21
WO1998028007A1 (en) 1998-07-02
TR199901968T2 (xx) 1999-12-21
EA002754B1 (ru) 2002-08-29
HUP0000829A3 (en) 2002-01-28
ES2224290T3 (es) 2005-03-01
DE69729880T2 (de) 2005-07-07
DK0948358T3 (da) 2004-11-08
EP0948358B1 (en) 2004-07-14
EP0948358B2 (en) 2011-11-23
AU5619198A (en) 1998-07-17
BG65418B1 (bg) 2008-07-31
SI0948358T2 (sl) 2012-03-30
JP2007204501A (ja) 2007-08-16
PL334365A1 (en) 2000-02-28
ES2224290T5 (es) 2012-03-12
PL193447B1 (pl) 2007-02-28
NZ512792A (en) 2002-11-26
NO327844B1 (no) 2009-10-05
EE04266B1 (et) 2004-04-15
CN1222315C (zh) 2005-10-12
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
JP5851695B2 (ja) 2016-02-03
PT948358E (pt) 2004-10-29
IS2070B (is) 2005-12-15
KR101042660B1 (ko) 2011-06-20
ATE270899T1 (de) 2004-07-15
CN1733296B (zh) 2010-05-26
KR20070052363A (ko) 2007-05-21
CA2275890A1 (en) 1998-07-02
EE200300127A (et) 2003-06-16
BG109523A (en) 2007-05-31
KR20000069664A (ko) 2000-11-25
DK0948358T4 (da) 2012-03-19
AU738362B2 (en) 2001-09-13
CZ300636B6 (cs) 2009-07-08
JP2012006979A (ja) 2012-01-12
EE9900313A (et) 2000-04-17
CA2275890C (en) 2011-11-01
NO993121D0 (no) 1999-06-23
IL130524A0 (en) 2000-06-01
CN1245434A (zh) 2000-02-23
IL130524A (en) 2005-08-31
BR9714434A (pt) 2000-05-02
SK284989B6 (sk) 2006-04-06
MX337876B (es) 2016-03-22
HU224222B1 (hu) 2005-06-28
DE69729880T3 (de) 2012-05-10
HK1025040A1 (en) 2000-11-03

Similar Documents

Publication Publication Date Title
NO993121L (no) Stabile flytende interferon-formuleringer
DK0975235T3 (da) Ernæringssammensætninger indeholdende oligosaccharider
KR950005324A (ko) 인슐린 제제
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
ATE83155T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
RU94046295A (ru) L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава
ATE22774T1 (de) Pflanzenschutzmittel in form von mischdispersionen.
AU5243901A (en) Repair of nerve damage
AU653371B2 (en) Pharmaceutical compositions
EP1930024A3 (en) G-CSF solution formulations having long-term stability
FI954914A7 (fi) Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin esto n, säätelyn tai regression aikaansaamiseksi
WO1995015391A3 (en) Aspergillus expression system
AU678421B2 (en) Highly concentrated TCF pharmaceutical preparations
AU8128691A (en) Hydrochloric acid donors as stabilizers for ACE inhibitor compositions
ATE416790T1 (de) Wasserlösliche trockene zusammensetzungen
AU3711597A (en) A novel galanin receptor
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
EP0508435A3 (en) Pharmaceutical composition of stabilized (leu 13)-motilin-hse
AU3525299A (en) Protein supplement, food composition containing same, preparation method and use
AU3371593A (en) Highly concentrated amino acid solution
AU5155699A (en) Peptides for inhibiting hpv e7 proteins
ES2007598A6 (es) Composicion a base de derivados de fosfonatos amonicos y procedimientopara regular con ella el crecimiento de las plantas.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN MA INC., US

MK1K Patent expired